The Senate Finance Committee today held a hearing on strategies to reduce prescription drug costs and encourage innovation and competition in the market. Health and Human Services Secretary Alex Azar testified on the administration’s blueprint to lower drug prices, released in May. In a statement submitted to the committee, AHA urged Congress to pass the Creating and Restoring Equal Access to Equivalent Samples Act to prevent anticompetitive behaviors used to block and delay entry of generic drugs; and H.R. 4392 to prevent a 30% reduction in Medicare payment to certain hospitals for outpatient drugs purchased under the 340B drug savings program, among other actions. Hospital spending on inpatient drugs increased 38.7% per admission between 2013 and 2015, more than three times the increase in spending for retail prescription drugs over the period, the statement notes.

Related News Articles

Headline
The Trump administration today announced steps drug manufacturers must take to lower prescription drug prices in the U.S. to "most favored nation" pricing, the…
Headline
The Department of Health and Human Services today issued a notice announcing a 340B Rebate Model Pilot Program as a voluntary mechanism for qualifying drug…
Headline
The Department of Health and Human Services May 20 announced it has identified specific pricing targets for pharmaceutical manufacturers to meet to satisfy…
Headline
The Centers for Medicare & Medicaid Services May 12 released draft guidance for the third round of negotiations for the Medicare Drug Price Negotiation…
Headline
The White House May 12 released an executive order to reduce prescription drug costs by allowing consumers to make direct purchases from drug manufacturers at…
Headline
The White House April 15 released an executive order directing federal agencies to undertake a broad range of tasks aimed at reducing the costs of prescription…